• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Ridgetech Inc.

    4/10/26 5:00:31 PM ET
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $RDGT alert in real time by email
    6-K 1 ea0285942-6k_ridgetech.htm REPORT OF FOREIGN PRIVATE ISSUER
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    For the month of April, 2026

     

    Commission File Number: 001-40724

     

    Ridgetech, Inc.

    (Translation of registrant’s name into English)

     

    Ming Zhao

    5th Floor, Building 6, No. 100, 18th Street, Baiyang Sub-district,

    Qiantang District, Hangzhou City, Zhejiang Province

    People’s Republic of China, 310008

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     

    INCORPORATION BY REFERENCE

     

    This report is incorporated by reference in our registration statements on Form F-3 (No. 333-291941) and S-8 (No. 333-264505, No. 333-268809 and No. 333-277849), and shall be deemed to be a part thereof from the date on which this report is furnished to the Securities and Exchange Commission (the “SEC”), to the extent not superseded by documents or reports subsequently filed or furnished.

     

    As previously reported, at the annual general meeting of shareholders of Ridgetech, Inc. (the “Company”) held on December 12, 2025 (the “2025 Annual Meeting”), the shareholders of the Company approved an ordinary resolution authorizing the board of directors of the Company (the “Board”) to effect a consolidation of the Company’s authorized and issued ordinary shares at a ratio of up to 1-for-200, with the exact ratio and effective date to be determined by the Board in its sole discretion (the “Ordinary Share Consolidation Proposal”). On March 27, 2026, pursuant to such authority, the Board approved a 1-for-150 reverse share split (the “Reverse Share Split”), to become effective at 5:00 p.m. Eastern Time on April 7, 2026 (the “Effective Date”).

     

    The Company is filing this report to disclose that the Effective Date has occurred and the Reverse Share Split has become effective. At the Effective Date, every 150 ordinary shares issued and outstanding immediately prior to the Effective Date (the “Old Ordinary Shares”), par value US$0.001 per share, were automatically combined into one ordinary share (the “New Ordinary Shares”), par value US$0.15 per share. The Reverse Share Split affected all shareholders uniformly and did not affect any shareholder’s percentage ownership interest in the Company, except for adjustments that may result from the treatment of fractional shares. No fractional shares were issued in connection with the Reverse Share Split; instead, any fractional entitlement resulting from the Reverse Share Split was rounded up to the nearest whole share.

     

    At the Effective Date, the Company’s authorized share capital was altered from US$36,010,000 divided into 36,000,000,000 ordinary shares with a par value of US$0.001 each and 10,000,000 preferred shares with a par value of US$0.001 each, to US$36,010,000 divided into 240,000,000 ordinary shares with a par value of US$0.15 each and 10,000,000 preferred shares with a par value of US$0.001 each. At the Effective Date, the 134,835,960 outstanding Old Ordinary Shares were reduced to approximately 898,918 outstanding New Ordinary Shares.

     

    The New Ordinary Shares began trading on a split-adjusted basis on The Nasdaq Capital Market at the opening of trading on April 8, 2026, under the symbol “RDGT”, but under a new CUSIP number (G2124G203).

     

    Shareholders who hold ordinary shares in “street name” through a brokerage account did not need to take any action as a result of the Reverse Share Split. Shareholders holding certificated ordinary shares or shares in book-entry registered form will receive instructions from the Company’s exchange agent and transfer agent, Equiniti Trust Company, LLC, regarding the exchange of Old Ordinary Shares for New Ordinary Shares.

     

    At the Effective Date, proportionate adjustments were made to the number of ordinary shares issuable upon exercise or settlement of the Company’s outstanding warrants and equity-based awards, and to the exercise prices thereof, in accordance with their respective terms. The number of ordinary shares reserved for issuance under the Company’s equity incentive plans was also proportionately reduced. These adjustments were made solely to reflect the Reverse Share Split and did not otherwise change the terms of any such warrants or equity-based awards.

     

    As previously reported, at the 2025 Annual Meeting, the shareholders of the Company approved a special resolution, subject to the shareholder approval of the Ordinary Share Consolidation Proposal and the Board having effected the consolidation of ordinary shares as authorized by the Ordinary Share Consolidation Proposal, that the Fifth Amended and Restated Memorandum and Articles of Association of the Company, a copy of which was attached to the proxy statement for the 2025 Annual Meeting as Annex A, subject to adjustment solely in respect of the final approved consolidation ratio, be adopted in substitution for, and to the exclusion of, the existing Fourth Amended and Restated Memorandum and Articles of Association of the Company to reflect the consolidation of ordinary shares. In connection with the effectiveness of the Reverse Share Split, the Company adopted and filed the Fifth Amended and Restated Memorandum and Articles of Association with the Registrar of Companies of the Cayman Islands to reflect the consolidation of the Company’s ordinary shares at the approved consolidation ratio. The Fifth Amended and Restated Memorandum and Articles of Association replaced the Company’s Fourth Amended and Restated Memorandum and Articles of Association in its entirety. A copy of the Fifth Amended and Restated Memorandum and Articles of Association is attached to this report as Exhibit 1.1.

     

    The Company currently has the active registration statements listed below (the “Registration Statements”) on file with the SEC on Form F-3 and Form S-8. SEC regulations permit the Company to incorporate by reference future filings made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, prior to the termination of the offerings covered by registration statements filed on Form F-3 or Form S-8, as applicable. The information incorporated by reference is considered to be part of the prospectus and prospectus supplements included within each of those registration statements. Information in this report is therefore intended to be automatically incorporated by reference into each of the Registration Statements listed below, thereby amending them. Pursuant to Rule 416(b) under the Securities Act of 1933, as amended, the number of undistributed ordinary shares deemed to be covered by each of the Registration Statements will be proportionately reduced to a number of New Ordinary Shares, as applicable, giving effect to the Reverse Share Split at the ratio of one-for-one hundred and fifty (1-for-150). The Registration Statements are as follows:(a) Registration Statement No. 333-291941 on Form F-3; and (b) Registration Statement Nos. 333-264505, 333-268809 and 333-277849 on Form S-8.

     

    Exhibit No.     Description of Exhibit 
    1.1     The Fifth Amended and Restated Memorandum and Articles of Association.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Date: April 10, 2026 RIDGETECH, INC.
         
      By: /s/ Ming Zhao
      Name:  Ming Zhao
      Title:  Interim Chief Executive Officer and Chief Financial Officer

     

    2

     

    Get the next $RDGT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RDGT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RDGT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ridgetech, Inc. Announces 1-for-150 Reverse Share Split

    HANGZHOU, China, April 3, 2026 /PRNewswire/ -- Ridgetech, Inc., a Cayman Islands exempted company (the "Company") (NASDAQ:RDGT), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced that it expects to implement a 1-for-150 reverse share split on its ordinary shares ("Ordinary Shares") effective Tuesday, April 7, 2026 at 5:00 p.m. Eastern Time, with trading to begin on a split‑adjusted basis at the market open on the next trading day. Trading in the Ordinary Shares will continue on the Nasdaq Capital Market under the symbol "RDGT." The new CUSIP number for the Ordinary Shares following the reverse share split is G2124G 203. As of April 2, 2026, the

    4/3/26 12:00:00 PM ET
    $CJJD
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Ridgetech Unveils 2026 Dual-Engine Growth Strategy to Drive Innovation and Value Creation

    HANGZHOU, China, March 4, 2026 /PRNewswire/ -- Ridgetech, Inc. (NASDAQ:RDGT) ("Ridgetech" or the "Company"), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced its dual-engine growth strategy for 2026. The strategy centers on supply chain integration by leveraging its wholesale distribution network, B2B platform, and franchise system. Building on its integrated pharmaceutical and healthcare service platforms, Ridgetech aims to achieve parallel breakthroughs in both business model innovation and value creation, thereby strengthening its long-term growth foundation across China's pharmaceutical and healthcare supply chain. Further Strengthening Co

    3/4/26 8:30:00 AM ET
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Ridgetech, Inc. Reports Fiscal Year 2025 Financial Results

    HANGZHOU, China, July 28, 2025 /PRNewswire/ -- Ridgetech, Inc. (Nasdaq: RDGT) ("Ridgetech" or the "Company"), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced its financial results for the fiscal year ended March 31, 2025. Mr. Frank Zhao, Interim Chief Executive Officer and Chief Financial Officer of Ridgetech, commented, "We are pleased to present a relatively stable revenue outcome for fiscal year 2025, a year marked by significant transformation for the Company. During this period, we divested our retail pharmacy business and acquired Ridgeline and its subsidiary, Allright (Hangzhou) Internet Technology Co. Ltd ("Allright"), marking our st

    7/28/25 9:00:00 AM ET
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $RDGT
    SEC Filings

    View All

    SEC Form 6-K filed by Ridgetech Inc.

    6-K - Ridgetech Inc. (0001856084) (Filer)

    4/10/26 5:00:31 PM ET
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 6-K filed by Ridgetech Inc.

    6-K - Ridgetech Inc. (0001856084) (Filer)

    4/3/26 12:00:02 PM ET
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form 6-K filed by Ridgetech Inc.

    6-K - Ridgetech Inc. (0001856084) (Filer)

    3/5/26 4:30:37 PM ET
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $RDGT
    Financials

    Live finance-specific insights

    View All

    Ridgetech, Inc. Reports Fiscal Year 2025 Financial Results

    HANGZHOU, China, July 28, 2025 /PRNewswire/ -- Ridgetech, Inc. (Nasdaq: RDGT) ("Ridgetech" or the "Company"), a wholesale distributor of pharmaceutical and other healthcare products in China, today announced its financial results for the fiscal year ended March 31, 2025. Mr. Frank Zhao, Interim Chief Executive Officer and Chief Financial Officer of Ridgetech, commented, "We are pleased to present a relatively stable revenue outcome for fiscal year 2025, a year marked by significant transformation for the Company. During this period, we divested our retail pharmacy business and acquired Ridgeline and its subsidiary, Allright (Hangzhou) Internet Technology Co. Ltd ("Allright"), marking our st

    7/28/25 9:00:00 AM ET
    $RDGT
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples